Diabetes Drug Delivery Devices Market is projected to be worth USD 31 billion by 2030

Stakeholders engaged in this domain are presently focusing on introducing advanced features, such as integrated continuous glucose monitoring (CGM) systems, artificial intelligence (AI) enabled algorithms, provisions for audiovisual / tactile feedback, and automatic drug reconstitution features. Such efforts are primarily directed towards differentiating proprietary offerings within a highlight competitive market landscape, and are expected to drive the market’s growth over the coming years.
Key Market Insights
More than 80 diabetes drug delivery devices are presently available / under development
More than 65% of the aforementioned devices are marketed, while the rest are being evaluated in preclinical / clinical studies. It is also worth highlighting that majority of the drug delivery devices intended for diabetics are insulin pumps (35%), followed by pen injectors / autoinjectors (32%).
Over 50 companies, across the world, claim to be engaged in developing drug delivery devices for diabetics
Majority (44%) of the device developers are located in North America, primarily in the US. Within Europe, most of the developers are distributed across France, Germany, Switzerland, Italy and UK. Further, around 37% of the players engaged in this domain are large firms.
The market is dominated by the products of big pharma players
The leading pharmaceutical companies (in terms of number of products and revenues shares) involved in this domain are large / very large businesses. It is worth mentioning that the aforementioned players are investing significantly in terms of number of marketed and clinical-stage drugs, partnerships and strategic investments in this domain.

Get Latest Market Insights: https://www.rootsanalysis.com/reports/diabetes-drug-delivery-devices-market/request-customization.html

Leave a Reply

Your email address will not be published. Required fields are marked *